Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$148 Mln
P/E Ratio
--
P/B Ratio
0.86
Industry P/E
--
Debt to Equity
0
ROE
-0.57 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
CA$-111.75 Mln
EBITDA
CA$-148.61 Mln
Net Profit
CA$-145.73 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cybin (CYBN)
| -20.92 | -0.64 | -27.27 | -47.55 | -33.10 | -- | -- |
|
BSE Sensex
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Cybin (CYBN)
| 38.05 | -75.25 | -19.46 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 32.31 | 241.03 | -- | -3.31 | |
| 0.57 | 50.55 | -- | -189.05 |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in... phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. Read more
Co-Founder, President & Executive Chairman
Mr. Eric So L.L.B.
Co-Founder, President & Executive Chairman
Mr. Eric So L.L.B.
Headquarters
Toronto, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cybin Inc (CYBN) stood at $ 267 Mln as on 31-Dec-24
The share price of Cybin Inc (CYBN) is $6.98 (NYSE) as of 28-Apr-2025 10:33 EDT. Cybin Inc (CYBN) has given a return of -33.1% in the last 3 years.
Cybin Inc (CYBN) has a market capitalisation of $ 148 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Cybin Inc (CYBN) is 0.86 times as on 25-Apr-2025, a 84% discount to its peers’ median range of 5.35 times.
Since, TTM earnings of Cybin Inc (CYBN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cybin Inc (CYBN) and enter the required number of quantities and click on buy to purchase the shares of Cybin Inc (CYBN).
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
The CEO & director of Mr. Eric So L.L.B.. is Cybin Inc (CYBN), and CFO & Sr. VP is Mr. Eric So L.L.B..
There is no promoter pledging in Cybin Inc (CYBN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
26
|
|
|
7
|
|
|
26
|
|
|
7
|
| Cybin Inc. (CYBN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cybin Inc (CYBN) was $0 Mln.
$-0.01
(
